Sarepta Therapeutics Inc
For the period ended Dec 31, 2023. Filed Feb 28, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Feb 28, 2024
SRPT$16.42-4.8%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Stockholders’ Equity
(in thousands)
| Accumulated | ||||||
|---|---|---|---|---|---|---|
| Additional · Other · Total | ||||||
| Common Stock · Paid-In · Comprehensive · Accumulated · Stockholders' | ||||||
| Shares | Amount | Capital | Income (Loss) | Deficit | Equity | |
| BALANCE AT DECEMBER 31, 2020 | 79,374 | $8 | $3,609,877 | $3 | $(2,848,129) | $761,759 |
| Cumulative effect of accounting change to adopt ASU 2020-06 | — | — | (156,953) | — | 60,161 | (96,792) |
| Exercise of options for common stock | 283 | — | 12,963 | — | — | 12,963 |
| Vest of restricted stock units/awards | 277 | — | — | — | — | — |
| Shares withheld for taxes | (18) | — | (1,432) | — | — | (1,432) |
| Issuance of common stock for cash, net of offering costs | 7,099 | 1 | 548,531 | — | — | 548,532 |
| Issuance of common stock under employee stock purchase plan | 112 | — | 7,839 | — | — | 7,839 |
| Stock-based compensation | — | — | 113,943 | — | — | 113,943 |
| Unrealized losses from available-for-sale securities, net of tax | — | — | — | (23) | — | (23) |
| Net loss | — | — | — | — | (418,780) | (418,780) |
| BALANCE AT DECEMBER 31, 2021 | 87,127 | 9 | 4,134,768 | (20) | (3,206,748) | 928,009 |
| Exercise of options for common stock | 318 | — | 22,573 | — | — | 22,573 |
| Vest of restricted stock units | 389 | — | — | — | — | — |
| Issuance of common stock under employee stock purchase plan | 116 | — | 7,470 | — | — | 7,470 |
| Stock-based compensation | — | — | 233,018 | — | — | 233,018 |
| Purchase of capped call share options for 2027 Notes | — | — | (127,305) | — | — | (127,305) |
| Partial settlement of capped call share options for 2024 Notes | — | — | 26,317 | — | — | 26,317 |
| Unrealized losses from available-for-sale securities, net of tax | — | — | — | (1,644) | — | (1,644) |
| Net loss | — | — | — | — | (703,488) | (703,488) |
| BALANCE AT DECEMBER 31, 2022 | 87,950 | 9 | 4,296,841 | (1,664) | (3,910,236) | 384,950 |
| Exercise of options for common stock | 528 | — | 40,485 | — | — | 40,485 |
| Vest of restricted stock units | 645 | — | — | — | — | — |
| Issuance of common stock for exchange of 2024 Notes | 4,456 | — | 693,377 | — | — | 693,377 |
| Partial settlement of capped call share options for 2024 Notes | — | — | 80,645 | — | — | 80,645 |
| Issuance of common stock under employee stock purchase plan | 153 | — | 10,761 | — | — | 10,761 |
| Stock-based compensation | — | — | 182,514 | — | — | 182,514 |
| Unrealized gains from available-for-sale securities, net of tax | — | — | — | 2,582 | — | 2,582 |
| Net loss | — | — | — | — | (535,977) | (535,977) |
| BALANCE AT DECEMBER 31, 2023 | 93,732 | $9 | $5,304,623 | $918 | $(4,446,213) | $859,337 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.